Medicine and Dentistry
Ovarian Cancer
100%
Systemic Therapy
75%
Medical Oncology
50%
Thyroid Cancer
50%
Targeted Therapy
43%
Progression Free Survival
38%
Cancer Therapy
37%
Molecular Imaging
31%
Overall Survival
30%
Disease
28%
Molecularly Targeted Therapy
25%
Side Effect
25%
Oncologist
25%
Lenvatinib
25%
Drug Dose Reduction
25%
End of Life Care
25%
Recurrent Ovarian Cancer
25%
Palbociclib
25%
Breast Cancer
25%
Protein Kinase Inhibitor
25%
Diagnosis
25%
Neck Mass
25%
Soft Tissue Sarcoma
25%
Therapeutic Drug Monitoring
25%
Pazopanib
25%
Malignant Neoplasm
20%
Neoplasm
18%
Genetic Transfection
18%
Bevacizumab
17%
Anaplastic Thyroid Carcinoma
16%
Neck
16%
Medical Care
16%
Quality of Life
13%
Paclitaxel
13%
Cancer Cell
12%
Tumor Cell
12%
PARP Inhibitor
10%
Intensive Care Unit
10%
Dose Densification
9%
Adverse Event
9%
Differential Diagnosis
8%
Rare Disease
8%
Early Diagnosis
8%
Pharmacokinetics
8%
Symptomatic Treatment
8%
Krukenberg Tumor
7%
Monoclonal Antibody
6%
Health Care
6%
Oncology
6%
Ovarian Tumor
6%
Keyphrases
Ovarian Cancer
30%
Paclitaxel Chemotherapy
28%
Oncologists
25%
Targeted Therapy
25%
Targeted Cancer Therapy
25%
Phase I Study
25%
Refractory Thyroid Cancer
25%
Lenvatinib
25%
Metformin
25%
Carboplatin-paclitaxel
25%
Advanced Ovarian Cancer
25%
Advanced Breast Cancer
25%
Rational Use
25%
Palbociclib
25%
Clinical Outcomes
25%
Dose Reduction
25%
Dosing Patterns
25%
Ovarian Cancer Screening
25%
Neck Mass
25%
Anaplastic Thyroid Cancer
25%
Diagnostic Work-up
25%
Clinical Impact
25%
Soft Tissue Sarcoma
25%
Therapeutic Drug Monitoring
25%
Pazopanib
25%
Clinical Feasibility
25%
Oncological Treatment
16%
Targeted Treatment
16%
Metabolism
16%
Aggressive Care
16%
Netherlands
16%
Cancer Cells
16%
Recommended Phase 2 Dose
15%
SELECT Trial
14%
Selpercatinib
12%
Fast-growing
12%
Short Stay
12%
Differential Diagnosis
12%
Rare Diseases
12%
Thyroid Lymphoma
12%
Early Diagnosis
12%
Additional Value
12%
Clinical Entities
12%
Fast Diagnostics
12%
Hemorrhagic Cyst
12%
Therapeutic Plan
12%
Rapid Growing
12%
Early Management
12%
Median Survival
12%
Dose-dense Paclitaxel
9%
Pharmacology, Toxicology and Pharmaceutical Science
Thyroid Cancer
50%
Progression Free Survival
35%
Overall Survival
33%
Ovary Cancer
31%
Chemotherapy
31%
Protein Kinase Inhibitor
25%
Protein Characterization
25%
Ovary Carcinoma
25%
Systemic Treatment
25%
Lenvatinib
25%
Gastrointestinal Stromal Tumor
25%
Paclitaxel
25%
Metformin
25%
Breast Cancer
25%
Carboplatin
25%
Palbociclib
25%
Imatinib
25%
Cohort Study
25%
Neck Tumor
25%
Soft Tissue Sarcoma
25%
Therapeutic Drug Monitoring
25%
Pazopanib
25%
Randomized Controlled Trial
25%
Adverse Event
22%
Neoplasm
18%
Pharmacokinetics
15%
Malignant Neoplasm
14%
Protein Tyrosine Kinase Inhibitor
11%
Disease
8%
Sunitinib
6%
Phosphotransferase Inhibitor
6%
Adjuvant
6%
Drug Development
6%
Tumor Growth
6%
Cabozantinib
6%
Vandetanib
6%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
6%
Effectiveness Study
6%
Clinical Trial
5%
Diarrhea
5%
